S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

$149.45
-4.94 (-3.20%)
(As of 03/28/2024 ET)
Today's Range
$149.32
$154.50
50-Day Range
$146.51
$189.70
52-Week Range
$143.52
$218.88
Volume
666,576 shs
Average Volume
869,824 shs
Market Capitalization
$18.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$216.12

Alnylam Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
44.6% Upside
$216.12 Price Target
Short Interest
Healthy
2.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.39mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.61) to ($2.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

33rd out of 938 stocks

Pharmaceutical Preparations Industry

14th out of 426 stocks

ALNY stock logo

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Stock Price History

ALNY Stock News Headlines

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
TD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)
Is Alnylam's HELIOS-B Delay A Red Flag?
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$216.12
High Stock Price Target
$395.00
Low Stock Price Target
$161.00
Potential Upside/Downside
+41.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
18 Analysts

Profitability

Net Income
$-440,240,000.00
Pretax Margin
-23.71%

Debt

Sales & Book Value

Annual Sales
$1.83 billion
Book Value
($1.76) per share

Miscellaneous

Free Float
124,183,000
Market Cap
$19.29 billion
Optionable
Optionable
Beta
0.39

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Yvonne L. Greenstreet M.B.A. (Age 61)
    MBChB, CEO & Director
    Comp: $2.09M
  • Mr. Jeffrey V. Poulton M.B.A.Mr. Jeffrey V. Poulton M.B.A. (Age 56)
    CFO & Executive VP
    Comp: $972.35k
  • Dr. Akshay K. Vaishnaw M.D. (Age 61)
    Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board
    Comp: $1.24M
  • Dr. Pushkal P. Garg M.D. (Age 56)
    Chief Medical Officer and Executive VP of Development & Medical Affairs
    Comp: $1M
  • Mr. Timothy J. Maines
    Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D. (Age 55)
    Senior VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom (Age 43)
    Senior VP of Investor Relations & Corporate Communications
  • Mr. Piyush Sharma J.D.
    Chief Ethics & Compliance Officer
  • Mr. Evan Lippman
    Chief Corporate Development & Strategy Officer
  • Ms. Kelley Boucher
    Chief Human Resource Officer

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Monday, March 25, 2024 at 11:46 PM.

Pros

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals focuses on developing novel therapeutics based on ribonucleic acid interference, a cutting-edge technology in the pharmaceutical industry that has shown promising results in treating various diseases.
  • The company has a diverse pipeline of investigational RNAi therapeutics targeting genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases, indicating potential for multiple revenue streams.
  • Alnylam Pharmaceuticals has a strong portfolio of marketed products including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, addressing rare diseases with high unmet medical needs, which can lead to stable revenue generation.
  • Strategic collaborations with reputable companies like Regeneron Pharmaceuticals and Roche demonstrate Alnylam's ability to leverage partnerships for research, development, and commercialization, enhancing growth prospects.
  • Recent positive market ratings and institutional ownership trends for Alnylam Pharmaceuticals, as well as the stock's performance, indicate investor confidence and potential for stock price appreciation.

Cons

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • Alnylam Pharmaceuticals operates in the highly competitive biopharmaceutical industry, facing challenges such as regulatory hurdles, clinical trial failures, and potential market saturation, which can impact financial performance.
  • The company's focus on rare diseases may limit its addressable market and scalability compared to companies targeting more prevalent conditions, potentially affecting long-term growth prospects.
  • Risks associated with clinical trial outcomes, drug approvals, and intellectual property protection are inherent in the biopharmaceutical sector, leading to uncertainties in revenue streams and profitability.
  • Dependency on a few key products for revenue generation exposes Alnylam Pharmaceuticals to risks of market fluctuations, patent expirations, and competition from emerging therapies, affecting financial stability.
  • Investing in pharmaceutical companies like Alnylam Pharmaceuticals carries inherent market risks, including macroeconomic factors, regulatory changes, and healthcare policy shifts that can influence stock performance and investor returns.

ALNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price target for 2024?

18 equities research analysts have issued 1-year price targets for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $161.00 to $395.00. On average, they anticipate the company's stock price to reach $216.12 in the next twelve months. This suggests a possible upside of 44.6% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2024?

Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of 2024. Since then, ALNY stock has decreased by 21.9% and is now trading at $149.45.
View the best growth stocks for 2024 here
.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 2,690,000 shares, a drop of 11.5% from the February 29th total of 3,040,000 shares. Based on an average daily trading volume, of 834,900 shares, the days-to-cover ratio is currently 3.2 days.
View Alnylam Pharmaceuticals' Short Interest
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The biopharmaceutical company earned $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. Alnylam Pharmaceuticals's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period last year, the business earned ($1.68) earnings per share.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Capital World Investors (12.89%), Vanguard Group Inc. (9.52%), Vanguard Group Inc. (9.48%), Baillie Gifford & Co. (5.55%), Dodge & Cox (2.92%) and Capital International Investors (2.86%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALNY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners